Harvard College

Massachusetts Institute of Technology

Washington University

Janssen Biotech, Inc.

Jeffrey R Millman

Alireza Rezania

Douglas A Melton

Felicia J Pagliuca

Michael Saris Segel

Clark K Colton

Benjamin Fryer

Quinn P Peterson

Mads Gurtler

Amanda R Dilenno

Jiwon Song

Daryl E Powers

Mads Gürtler

Michael Saris Segal

Disclosed herein are methods, compositions, kits, and agents useful for inducing β cell maturation, and isolated populations of SC-β cells for use in various applications, such as cell therapy.

SC-beta cells and compositions and methods for generating the same

Disclosed herein are methods, compositions, kits, and agents useful for inducing &#x3b2; cell maturation, and isolated populations of SC-&#x3b2; cells for use in various applications, such as cell therapy.

Disclosed herein are methods for generating SC-&#x3b2; cells, and isolated populations of SC-&#x3b2; cells for use in various applications, such as cell therapy.

Methods for generating stem cell-derived beta cells and uses thereof

Disclosed herein is a 3D-printed, biocompatible macroporous device that houses stem cell derived &#x3b2;-cell (SC-&#x3b2; cell) clusters within a degradable fibrin gel. Cluster sizes are used that avoid severe hypoxia within 3D-printed devices and a microwell-based technique is used for resizing clusters within this range. 3D-printed devices may function for at least 12 weeks, are retrievable, and maintain structural integrity.

3D-printed scaffold device for cell transplantation

Methods for generating stem cell-derived &#x3b2; cells and uses thereof

The invention provides methods and compositions relating to differentiated cell populations that derive from pluripotent stem cells. The methods relate to reducing the number of residual stem cells present in such populations. The compositions include differentiated cell populations that contain reduced number of stem cells or that contain no stem cells. Pluripotent stem cells may be reduced in number and/or function through exposure to low oxygen levels.

Methods and compositions for increased safety of stem cell-derived populations

SC-&#x3b2; cells and compositions and methods for generating the same

The invention provides inter alia methods for differentiating embryonic stem cells into insulin producing cells, as well as compositions comprising such cells, and therapeutic uses of such compositions.

Method for differentiating human embryonic stem cells into &#x3b2;-cells for the treatment of type I diabetes

The invention provides methods for differentiating pluripotent stem cells such as ES cells with improved progenitor and differentiated cell yield using low oxygen conditions and optionally in the absence of exogenously added differentiation factors.

Growing community of inventors

St. Louis, MO, United States of America

Jeffrey R Millman